Clinical trials in Nice – page 69

961 clinical trials in Nice, France across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Nice at a glance

961

clinical trials

Research sites4

Quick filters

961 trials in Nice

Open in trial search

Myelodysplastic syndrome

Not recruiting

Study of Tamibarotene and Azacitidine Treatment in Newly Diagnosed Adults with RARA-positive Higher-risk Myelodysplastic Syndrome (MDS)

Registered drug

Study of Tamibarotene and Azacitidine Treatment in Newly Diagnosed Adults with RARA-positive Higher-risk Myelodysplastic Syndrome (MDS)

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Syros Pharmaceuticals Inc.

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study of palbociclib with hormone therapy guided by ESR1 mutation monitoring in patients with ER-positive, HER2-negative metastatic breast cancer

Registered drugNo placebo

Study of palbociclib with hormone therapy guided by ESR1 mutation monitoring in patients with ER-positive, HER2-negative metastatic breast cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:Unicancer

Contact Research Centre

Immune-mediated enterocolitis+1

Not recruiting

Study on MAS825 for Patients with Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

Registered drug

Study on MAS825 for Patients with Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

Registered drug

France

Participants:0–17 years · 18–64 years
Substances:Ciclosporin
Sponsor:Novartis Pharma AG

Contact Research Centre

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis Using Topical Corticosteroids

Registered drug

Study on the Effectiveness and Safety of Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis Using Topical Corticosteroids

Registered drug

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Amlitelimab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Transitional cell carcinoma

Not recruiting

Study of Disitamab Vedotin and Pembrolizumab for Patients with Untreated Advanced Urothelial Cancer Expressing HER2

Registered drugNo placebo

Study of Disitamab Vedotin and Pembrolizumab for Patients with Untreated Advanced Urothelial Cancer Expressing HER2

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Seagen Inc.

Contact Research Centre

Pancreatic carcinoma metastatic

Not recruiting

Study of Zolbetuximab with Nab-Paclitaxel and Gemcitabine for Adults with Metastatic Pancreatic Cancer

Registered drugNo placebo

Study of Zolbetuximab with Nab-Paclitaxel and Gemcitabine for Adults with Metastatic Pancreatic Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Gemcitabine
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Pulmonary arterial hypertension

Not recruiting

Study on Long-term Safety of Seralutinib for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo

Study on Long-term Safety of Seralutinib for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Seralutinib
Sponsor:GB002 Inc.

Contact Research Centre

Chronic kidney disease+1

Not recruiting

Study on Low Dose Rivaroxaban for Heart and Blood Vessel Disease in Patients with Advanced Kidney Disease or on Dialysis

Investigational

Study on Low Dose Rivaroxaban for Heart and Blood Vessel Disease in Patients with Advanced Kidney Disease or on Dialysis

Investigational

France

Participants:18–64 years · 65+ years
Substances:Rivaroxaban
Sponsor:The George Institute For Global Health

Contact Research Centre

Chronic myeloid leukaemia

Not recruiting

Study on the Tolerability and Efficacy of Asciminib vs. Nilotinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Registered drugNo placebo

Study on the Tolerability and Efficacy of Asciminib vs. Nilotinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Nilotinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Risankizumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Risankizumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Hormone-dependent prostate cancer

Not recruiting

Study of Capivasertib and Abiraterone for Patients with Metastatic Hormone-Sensitive Prostate Cancer with PTEN Deficiency

Registered drug

Study of Capivasertib and Abiraterone for Patients with Metastatic Hormone-Sensitive Prostate Cancer with PTEN Deficiency

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:AstraZeneca AB

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Nice

What the registry says about research in the country

01 Neurological Disorders

Innovative research focusing on neurodegenerative conditions and movement disorders, including trials evaluating new treatments for Amyotrophic Lateral Sclerosis and Essential Tremor.

ALS Treatment Development
Movement Disorder Therapies
Multiple Sclerosis Management

Studies aim to improve quality of life and slow disease progression through targeted therapeutic approaches.

02 Autoimmune Conditions

Comprehensive research into inflammatory disorders, including studies on Psoriatic Arthritis and innovative treatments for various autoimmune conditions.

Psoriasis Management
Inflammatory Disease Therapy
Myasthenia Gravis Treatment

Focus on developing targeted therapies and combination treatments for better disease control.

03 Oncology Research

Advanced studies in cancer treatment, particularly focusing on head and neck cancers and innovative approaches in lung cancer therapy.

Head and Neck Cancer Treatments
Neuroendocrine Carcinomas
Prostate Cancer Therapy

Investigating combination therapies and targeted treatments for improved patient outcomes.

04 Gastrointestinal Disorders

Groundbreaking research in inflammatory bowel diseases, including novel approaches for Crohn's Disease and Ulcerative Colitis treatment.

Microbiota Transplantation
IBD Management
Novel Therapeutic Approaches

Exploring innovative therapeutic strategies and microbiome-based treatments.

05 Infectious Disease Prevention

Critical research in HIV prevention and treatment, focusing on long-acting preventive medications and innovative therapeutic approaches.

HIV Pre-Exposure Prophylaxis
Long-Acting Treatments
Prevention Strategies

Development of new preventive measures and treatment options for at-risk populations.

Back to France All countries